A carregar...
Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study
OBJECTIVE: Assess golimumab efficacy/safety through 5 years in patients with active ankylosing spondylitis (AS). METHODS: 356 patients with AS were randomly assigned to placebo, golimumab 50 mg or 100 mg every 4 weeks. At week 16, patients with inadequate response early escaped with blinded dose adj...
Na minha lista:
| Publicado no: | Ann Rheum Dis |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BMJ Publishing Group
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4392310/ https://ncbi.nlm.nih.gov/pubmed/25387477 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2014-205862 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|